SCHEMBL30765443

SCHEMBL30765443

O=C(Cn1c(-c2ccccc2)ncc(NC(=O)c2coc(-c3cccnc3)n2)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ELANE P08246 4/20 0.39
NTRK1 P04629 2/20 0.38
CASP1 P29466 1/20 0.38
CMA1 P23946 3/20 0.38
CTRC Q99895 3/20 0.38
NTRK3 Q16288 1/20 0.37
IRAK4 Q9NWZ3 2/20 0.36
EGLN1 Q9GZT9 1/20 0.36
DGAT2 Q96PD7 1/20 0.35
F2 P00734 1/20 0.35
ALDH1A1 P00352 1/20 0.35
USP2 O75604 1/20 0.35
MAPT P10636 1/20 0.35
HDAC6 Q9UBN7 1/20 0.34
F3 P13726 1/20 0.34
TBXA2R P21731 1/20 0.34
TBXAS1 P24557 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765889 0.92 ELANE (0.38) ELANENTRK1CASP1CMA1CTRC
SCHEMBL30765466 0.90 DGAT2 (0.47) ELANECASP1CMA1CTRCEGLN1
SCHEMBL30765627 0.90 DGAT2 (0.39) NTRK1NTRK3IRAK4DGAT2F2
SCHEMBL31558568 0.84 NTRK1 (0.45) ELANENTRK1CASP1CMA1CTRC
SCHEMBL30766050 0.83 ELANE (0.41) ELANENTRK1CASP1CMA1CTRC
SCHEMBL30765732 0.83 NTRK1 (0.40) ELANENTRK1CASP1CMA1CTRC
SCHEMBL30766058 0.83 ELANE (0.43) ELANECASP1IRAK4EGLN1HDAC6
SCHEMBL30765851 0.83 NTRK1 (0.40) ELANENTRK1CASP1CMA1CTRC
SCHEMBL30765478 0.82 CASP1 (0.41) ELANENTRK1CASP1CMA1CTRC
SCHEMBL30765697 0.81 F2 (0.43) ELANENTRK1CASP1CMA1CTRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed